Please ensure Javascript is enabled for purposes of website accessibility

Why BioXcel Therapeutics Is Soaring Today

By Prosper Junior Bakiny – Jul 20, 2020 at 10:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported positive results from two pivotal clinical trials.

What happened?

BioXcel Therapeutics (BTAI -0.44%) is starting the week on a strong note. As of 11:31 a.m. EDT on Monday, shares of the biotech company are up by 14.4%. There seem to be two major catalysts for these gains. First, BioXcel reported positive results from two clinical trials for one of its lead pipeline candidates. Second, a Wall Street analyst reiterated his buy rating and increased his price target on the company's stock.

So what

BioXcel's BXCL501 is a sublingual thin film that the company is developing for the treatment of acute agitation (psychological and behavioral symptoms) associated with psychiatric conditions such as schizophrenia and bipolar disorder. Today, the company reported that BXCL501 achieved its primary and secondary endpoints in two phase 3 clinical trials. In both of these studies, "BXCL501 was well tolerated, with rapid and durable reductions in agitation," in patients with schizophrenia and bipolar disorder.

Man on a ladder drawing upward pointing graph on a board.

Image source: Getty Images.

In addition to these excellent clinical trial results, H.C. Wainwright analyst Ram Selvaraju reiterated a buy rating on BioXcel, giving the stock a price target of $200. At writing, shares of BioXcel are trading for about $60.10 apiece, which means the stock still has a lot of room to grow, at least according to Selvaraju.

Now what

According to BioXcel, existing therapies for acute agitation associated with psychiatric disorders are inadequate. And given that there are roughly 9.7 million patients who experience agitations each year, this could represent an exciting opportunity for the biotech company. After this morning's gains, BioXcel's stock is up by 314.2% year to date. The company is gearing up to submit BXCL501 to regulatory authorities for review, and given the results from these clinical studies, the treatment will likely be approved. In other words, BioXcel's shares aren't done climbing. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioXcel Therapeutics, Inc. Stock Quote
BioXcel Therapeutics, Inc.
$11.20 (-0.44%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.